Cortexyme is developing novel treatments for altering the course of neurodegenerative diseases.

Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer’s and other degenerative disorders.

Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.

More info